Alzheimer’s Disease Market

Alzheimer’s Disease Market (2nd edition) by Type of Treatment (Symptomatic and Disease Modifying), Symptomatic Indications (Dementia, Insomnia and Other Psychological Symptoms) and Geography (North America, Europe and Asia-Pacific), 2021-2035

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    198

  • Pages
    150

  • View Count
    23703

Alzheimer’s Disease Market Overview

The Alzheimer’s disease market is estimated to be worth $7.6 billion in 2022 and is expected to grow at CAGR of 12% during the forecast period. Alzheimer’s disease is a progressive neurological disorder characterized by the death of brain cells, eventually leading to memory loss, cognitive dysfunction and dementia. Accounting for 60-70% cases of dementia, Alzheimer’s disease is known to be the sixth leading cause of death in the US. Presently, more than 6 million Americans of all ages are living with Alzheimer's and this number is projected to reach around 13 million by 2050. In 2020, the healthcare burden associated with the disease was estimated to be around USD 305 billion. Given the socioeconomic burden associated with Alzheimer’s, pharmaceutical players have been on the lookout for reliable diagnostic tests and effective alzheimers treatment alternatives that can slow the progression of this disease. However, not many drugs could make their way to the market and majority of the existing therapeutic approaches have proven ineffective in the treatment of Alzheimer’s disease and its related symptoms.

Recently, in June 2021, the FDA granted accelerated approval for the first disease modifying therapy, Aduhelm™ (Aducanumab), developed by Biogen, for the alzheimers treatment. The approval of this amyloid beta-directed antibody has sparked a ray of hope for other players which are seeking approval for similar therapies. Further, multiple partnerships have been forged by various established players and start-ups in this domain in order to expand their research efforts and respective product portfolios. In addition, venture capital and other strategic investors are providing the necessary financial support to the research initiatives being undertaken by start-ups. Given the ongoing efforts aimed at finding effective and potential therapeutic cure, we are led to believe that the Alzheimer’s disease market is likely to witness healthy market growth during the forecast period.

List of Marketed and Clinical Development Pipeline of Alzheimer’s Disease Drug Candidate Market Landscape of Drugs Developed for the Treatment of Alzheimer’s Publication Analysis in Alzheimer's Disease Market

Key Drug Developers in Alzheimer’s Disease Market

Example of key drug developers engaged in Alzheimer’s disease market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie, AC Immune, Biogen, Eisai, Eli Lilly and Company, GlaxoSmithKline, Grifols, Janssen Pharmaceutical, Neurim Pharmaceuticals, Novartis, Novo Nordisk, Roche and Takeda Pharmaceutical. This Alzheimer’s drug market report includes an easily searchable excel database of all the companies developing drugs for Alzheimer’s disease, worldwide.

Recent Developments in Alzheimer’s Disease Market:

Several recent developments have taken place in the field of Alzheimer’s drug market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In August 2023, Beckman Coulter entered into a collaboration with Fujirebio with an aim to combine their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative disease such as Alzheimer's diseases. 
  • In July 2023, Eisai announced that the FDA has approved the LEQEMBI® (lecanemab-irmb) under the accelerated approval pathway, making LEQEMBI the first and only approved anti-amyloid Alzheimer's disease treatment shown to reduce the rate of disease progression and to slow cognitive impairment in the early and mild dementia stages of the disease. 
  • In June 2023, Aptamer Group collaborated with Neuro-Bio with an aim to develop Alzheimer’s disease diagnostic test.

Scope of the Report

The “Alzheimer’s Disease Market (2nd Edition) by Type of Treatment (Symptomatic and Disease Modifying), Symptomatic Indications (Dementia, Insomnia and Other Psychological Symptoms) and Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2021-2035” market report features an extensive study on the current market landscape, market size, market share, market forecast, market outlook and future opportunities for the Alzheimer’s drug market. The market research report underlines an in-depth analysis, highlighting the capabilities of various stakeholders engaged in Alzheimer’s disease market.

Patent Analysis in Alzheimer's Disease Market Clinical Trials Analysis in Alzheimer's Disease Market Terminated Clinical Trials Analysis in Alzheimer's Disease Market

Amongst other elements, the market research report features:

  • A detailed review of the current market landscape of drugs developed for the alzheimers treatment, including analyses based on several relevant parameters, such as current status of development (marketed, clinical and pre-clinical), phase of development (phase IV, phase III, phase II/III, phase II, phase I/II and phase I) of lead candidates, type of biologic (antibodies, peptides, cell and gene therapy, protein and vaccines), target disease stage (early stage, mild stage, mild to moderate stage and moderate to severe stage), type of treatment (symptomatic treatment, disease modifying treatment and both), mechanism of action (inhibitor, activator and modulator), route of administration (oral, intravenous, subcutaneous and others), dosing frequency (single dose, daily, twice daily, thrice daily, weekly, biweekly, monthly) type of therapy (monotherapy and combination therapy) and path to clinic (dedicated, repositioned and repurposed). Additionally, the report provides information on drug developer(s) involved in the domain, along with analyses based on a number of relevant parameters, such as year of establishment, company size and geographical location of headquarters.
  • A detailed analysis of completed, ongoing and planned clinical trials of the drugs for the treatment of Alzheimer’s disease and its related symptoms, on the basis of several relevant parameters, such as trial status, trial registration year, type of sponsor / collaborator, type of study design, enrolled patient population, age category, leading industry sponsors / collaborators (in terms of number of trials conducted) and regional distribution of trials.
  • Elaborate profiles of the key players involved in the development of therapeutics for Alzheimer’s disease. Each profile features a brief overview of the company, its financial information, details on its product portfolio, and recent developments and an informed future outlook.
  • An in-depth analysis of grants that have been awarded to various research institutes for projects related to Alzheimer’s disease, in the period between 2017 and 2021, on the basis of important parameters, such as year of grant award, grant amount awarded, administering institute center, support period, type of grant application, grant activity code, emerging focus area, purpose of grant award, type of recent organization, popular NIH department and prominent program officers. 
  • An analysis of the partnerships established between various stakeholders in Alzheimer’s disease market, during the period 2017-2021, covering product development and commercialization agreements, R&D agreements, technology / product licensing agreements, other licensing agreements, mergers and acquisitions, clinical trial agreements and other relevant types of deals. 
  • A review of the funding and investments made in Alzheimer’s drug market, in the period between 2017 and 2021, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development. The analysis has been done on the basis of several parameters, such as number of funding instances, amount invested, type of funding, leading players and investors, and geographical analysis.
  • A detailed assessment of discontinued drugs and terminated trials, providing information on the year of discontinuation, reason(s) for discontinuation, phase of discontinuation, mechanism of action of the terminated drugs, type of indication, reason for termination, affiliated stakeholders. 
  • A detailed review of around 20,000 peer-reviewed, scientific articles related to research on Alzheimer’s disease, which have been published between 2017 and June 2021, including analysis based on parameters, such as year of publication, key focus area, type of molecule, popular keywords, and key journals (in terms of number of articles published in Alzheimer’s disease market and impact factor of the journal).
  • An in-depth analysis of the patents related to Alzheimer’s disease, filed / granted since 2017, based on various parameters, such as patent publication year, geographical location / patent jurisdiction, CPC symbols, emerging focus areas, and type of applicant, and leading players (by number of patents). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
Partnerships Activities in Alzheimer's Disease Market Funding and Investment Activities in Alzheimer's Disease Market Market Forecast and Opportunity Analysis in Alzheimer's Disease Market

The key objective of Alzheimer’s disease market report is to provide a detailed market analysis in order to estimate the existing Alzheimer's drug market size, market value, statistics and future opportunity for Alzheimer’s disease market during the forecast period. Based on multiple parameters, such as disease prevalence, anticipated adoption rates and the selling price / likely selling price of therapies for the disease, we have developed informed estimates on the evolution of the market for the forecast period 2021-2035. The market report also features the likely distribution of the current and forecasted opportunity across [A] type of treatment (symptomatic and disease modifying treatment) [B] symptomatic indications (dementia, insomnia and other psychological symptoms) and [C] key geographical regions (North America, Europe and Asia-Pacific). To account for the future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, portraying different tracks of the anticipated industry’s growth. The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in Alzheimer’s disease market. The market research report features detailed transcripts of interviews held with the following industry stakeholders:

  • Kenneth Moch (President and Chief Executive Officer, Cognition Therapeutics)
  • Mathias Schmidt (Chief Executive Officer, ArmaGen)
  • Ram Bhatt (Chief Executive Officer, Chairman and Founder, ICB International)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is Alzheimer’s disease?

Answer: Alzheimer’s disease is a progressive disorder under which, brain cells and intercellular connections start degenerating over the years, leading to loss of memory and other mental functions.

Question 2: How big is the Alzheimer’s disease market?

Answer: The Alzheimer’s disease market size is estimated to be worth $7.6 billion in 2022.

Question 3: What is the projected market growth of the Alzheimer’s disease market?

Answer: The Alzheimer’s disease industry is expected to grow at compounded annual growth rate (CAGR) of over 12% during the forecast period 2021 - 2030.

Question 4: Who are the leading drug developers in the Alzheimer’s disease market?

Answer: Examples of key drug developers engaged in Alzheimer’s disease market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie, AC Immune, Biogen, Eisai, Eli Lilly and Company, GlaxoSmithKline, Grifols, Janssen Pharmaceutical, Neurim Pharmaceuticals, Novartis, Novo Nordisk, Roche and Takeda Pharmaceutical.

Question 5: How many clinical trials have been registered for evaluating Alzheimer’s disease therapeutics?

Answer: More than 2,000 clinical trials have been registered for evaluating different Alzheimer’s disease therapeutics.

Question 6: How many companies are currently engaged in the Alzheimer’s disease market?

Answer: Over 160 companies are currently developing drugs for Alzheimer’s disease.

Question 7: Which region emerged as the hub for companies engaged in the Alzheimer’s disease market?

Answer: North America emerged as the hub for drug developers engaged in the Alzheimer’s disease market, with 60% of the players established in the region.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com